Hemoglobin Lepore syndrome

Lore & Background

Hemoglobin Lepore syndrome was first identified in the Lepore family, an Italian-American family, in 1958. The condition arises from a crossover between the delta (HBD) and beta globin (HBB) gene loci during meiosis, resulting in a fusion chain. Three varieties exist: Washington (also called Boston or Washington-Boston), Baltimore, and Hollandia. Each variety is distinguished by a different fusion point and slightly different electrophoretic and chromatographic properties, though hematological findings resemble beta-thalassemia trait.

Reader's Guide

Hemoglobin Lepore syndrome is significant as a model of gene fusion causing hemoglobinopathy. The homozygous state is rare but can present with severe anemia, splenomegaly, hepatomegaly, and skeletal abnormalities similar to homozygous beta-thalassemia. Patients of Balkan descent tend to have the most severe presentation. A potential complication in children with acute anemia (hemoglobin below 5.5 g/dl) is silent stroke, which causes brain damage and increases risk of future stroke. The heterozygote form is mildly anemic with hypochromia and microcytosis. Diagnosis uses CBC, CE-HPLC, hemoglobin electrophoresis, and DNA analysis. Management for severe cases includes regular blood transfusions; heterozygotes require no treatment. The trait has worldwide distribution, with varieties more prevalent in specific ethnic groups: Washington in Southern Italians, Baltimore in Balkan populations, and Hollandia in Papua New Guinea and Bangladesh.

Did You Know?

• The three varieties are Washington (Boston), Baltimore, and Hollandia, each with a distinct fusion point.
• Severity of symptoms in homozygous Hb Lepore patients varies widely and is not specifically tied to Balkan descent.
• Severe anemia in children with Hemoglobin Lepore syndrome carries general risks, but silent stroke is not a highlighted complication for this condition.